Open AccessHigh-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome
Author(s) -
Anne-Sophie Chrétien,
Raynier Devillier,
Samuel Granjeaud,
Charlotte Cordier,
Clémence Demerle,
N. Salem,
Julia Wlosik,
Florence Orlanducci,
Laurent Gorvel,
Stéphane Fattori,
MarieAnne Hospital,
Jihane Pakradouni,
Emilie Gregori,
Magali Paul,
Philippe Rochigneux,
Thomas Pagliardini,
Mathieu Morey,
Cyril Fauriat,
Nicolas Dulphy,
Antoine Toubert,
Hervé Luche,
Marie Malissen,
Didier Blaise,
Jacques A. Nunès,
Norbert Vey,
Daniel Olive
Publication year - 2021
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2020459118
Subject(s) - nkg2d , cd16 , interleukin 21 , mass cytometry , natural killer cell , janus kinase 3 , immunology , k562 cells , flow cytometry , immune system , nk 92 , biology , interleukin 12 , lymphokine activated killer cell , innate immune system , myeloid leukemia , cancer research , leukemia , t cell , cytotoxic t cell , cd8 , phenotype , in vitro , cd3 , biochemistry , gene
Significance This work provides a report of accumulation of unconventional CD56− CD16+ NK cells in nonvirally induced malignancies. Increased frequency of CD56− CD16+ NK cells is associated with adverse clinical outcome in AML, as well as other maturation defects, and might contribute to a defective control of AML progression. Pseudotime analysis highlights a disruption in the maturation process of conventional NK cells in AML patients, leading to a bifurcation point absent in healthy subjects. This analysis, combined with the reduced frequency of conventional NK cells observed in AML patients, suggests that unconventional CD56− CD16+ NK cells derive from an aberrant maturation of conventional NK cells. Overall, accumulation of CD56− CD16+ NK cells could be an important feature of immune escape from innate immunity.